## Disclosures

### Personal Commercial (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (5)

<table>
<thead>
<tr>
<th>Trial Name</th>
<th>Trial Sponsor</th>
<th>Trial Funding Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capricore Open Label Extension</td>
<td>Capricor A Therapeutics, Inc.</td>
<td></td>
</tr>
<tr>
<td>Multicenter Randomized Trial of Everolimus in Pediatric Heart Transplant</td>
<td>Department of Defense</td>
<td></td>
</tr>
<tr>
<td>PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY WITH OPEN-LABEL EXTENSION, TO ASSESS THE EFFICACY AND SAFETY OF RILONACEPT TREATMENT IN SUBJECTS WITH RECURRENT PERICARDITIS</td>
<td>Kiniksa Pharmaceuticals, Ltd.</td>
<td></td>
</tr>
<tr>
<td>Tolerability and Pharmacokinetics of LCZ696 (Entresto) in Pediatrics</td>
<td>Novartis Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Carmeseal-MD in DMD patients</td>
<td>Phrixus Pharmaceuticals, Inc.</td>
<td></td>
</tr>
</tbody>
</table>

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

## Agreement

**Certified Education Attestation** | Signed on 8/3/2020
URL for full agreement: [http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 8/3/2020
URL for full agreement: [http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

**Embargo** | Signed on 8/3/2020
URL for full agreement: [http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

**On-Going Obligation Agreement** | Signed on 8/3/2020

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College’s integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.